Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 30, 2017

DrugPatentWatch Database Preview

ORENITRAM Drug Profile

« Back to Dashboard

Which patents cover Orenitram, and what generic Orenitram alternatives are available?

Orenitram is a drug marketed by United Therap and is included in one NDA. There are fourteen patents protecting this drug and two Paragraph IV challenges.

This drug has sixty-two patent family members in eleven countries.

The generic ingredient in ORENITRAM is treprostinil diolamine. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the treprostinil diolamine profile page.

Summary for Tradename: ORENITRAM

Suppliers / Packagers: see list2
Bulk Api Vendors: see list16
Clinical Trials: see list4
Patent Applications: see list109
Drug Prices:see details
DailyMed Link:ORENITRAM at DailyMed

Pharmacology for Tradename: ORENITRAM

Ingredient-typeProstaglandins I
Drug ClassProstacycline Vasodilator
Physiological EffectVasodilation
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
United Therap
treprostinil diolamine
TABLET, EXTENDED RELEASE;ORAL203496-005Oct 7, 2016RXYesNo8,497,393► SubscribeY ► Subscribe
United Therap
treprostinil diolamine
TABLET, EXTENDED RELEASE;ORAL203496-003Dec 20, 2013RXYesNo9,050,311► SubscribeYY ► Subscribe
United Therap
treprostinil diolamine
TABLET, EXTENDED RELEASE;ORAL203496-002Dec 20, 2013RXYesNo► Subscribe► Subscribe
United Therap
treprostinil diolamine
TABLET, EXTENDED RELEASE;ORAL203496-003Dec 20, 2013RXYesNo► Subscribe► Subscribe
United Therap
treprostinil diolamine
TABLET, EXTENDED RELEASE;ORAL203496-004Dec 20, 2013RXYesYes8,410,169► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Drug patents and clinical trials in dozens of countries
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus